58.51

0.95% -0.56

Biomarin Pharmaceutical Inc (BMRN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$59.07

Aprire:

$59.19

Volume 24 ore:

1.18M

Relative Volume:

0.49

Capitalizzazione di mercato:

$11.25B

Reddito:

$2.95B

Utile/perdita netta:

$523.88M

Rapporto P/E:

21.75

EPS:

2.69

Flusso di cassa netto:

$620.18M

1 W Prestazione:

-4.27%

1M Prestazione:

-2.27%

6M Prestazione:

+8.17%

1 anno Prestazione:

-17.12%

Intervallo 1D:

$58.23

$60.71

Intervallo di 1 settimana:

$58.23

$61.97

Portata 52W:

$50.76

$73.18

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Nome

Biomarin Pharmaceutical Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(415) 506-6700

Indirizzo

105 DIGITAL DRIVE, NOVATO, CA

Dipendente

3,221

Cinguettio

Prossima data di guadagno

2026-02-23

Ultimi documenti SEC

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BMRN Biomarin Pharmaceutical Inc	58.51	11.25B	2.95B	523.88M	620.18M	2.69
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2026-01-20	Aggiornamento	Canaccord Genuity	Hold → Buy
2025-12-03	Downgrade	Leerink Partners	Outperform → Market Perform
2025-11-06	Downgrade	Stifel	Buy → Hold
2025-09-08	Iniziato	H.C. Wainwright	Neutral
2025-09-03	Iniziato	Raymond James	Outperform
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-02-24	Aggiornamento	Oppenheimer	Perform → Outperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-30	Downgrade	William Blair	Outperform → Mkt Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-20	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-05-17	Downgrade	Robert W. Baird	Outperform → Neutral
2024-05-14	Iniziato	Evercore ISI	Outperform
2023-11-15	Iniziato	Wells Fargo	Overweight
2023-10-23	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-09-28	Iniziato	Raymond James	Mkt Perform
2023-09-18	Iniziato	UBS	Buy
2023-07-27	Iniziato	Scotiabank	Sector Perform
2023-07-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-03-21	Iniziato	Bernstein	Underperform
2023-02-22	Downgrade	Oppenheimer	Outperform → Perform
2023-02-21	Iniziato	Citigroup	Neutral
2023-01-30	Iniziato	BMO Capital Markets	Market Perform
2023-01-18	Iniziato	Canaccord Genuity	Hold
2022-10-31	Aggiornamento	Oppenheimer	Perform → Outperform
2022-07-13	Iniziato	Cantor Fitzgerald	Overweight
2022-06-13	Ripresa	Wedbush	Neutral
2022-04-25	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-10-07	Ripresa	Jefferies	Buy
2021-09-09	Aggiornamento	Stifel	Hold → Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-04	Ripresa	Guggenheim	Buy
2021-03-01	Aggiornamento	Evercore ISI	In-line → Outperform
2020-08-20	Downgrade	Citigroup	Buy → Neutral
2020-08-20	Downgrade	William Blair	Outperform → Mkt Perform
2020-08-19	Downgrade	Evercore ISI	Outperform → In-line
2020-08-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	Downgrade	Stifel	Buy → Hold
2020-07-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	Reiterato	Citigroup	Buy
2020-01-28	Iniziato	BMO Capital Markets	Market Perform
2020-01-27	Iniziato	BMO Capital Markets	Market Perform
2020-01-24	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-12	Iniziato	SunTrust	Buy
2019-10-17	Ripresa	BofA/Merrill	Buy
2019-05-23	Ripresa	Citigroup	Buy
2019-04-09	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-07	Reiterato	Stifel	Buy
2018-08-03	Reiterato	Stifel	Buy

Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

Mar 14, 2026

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st

Mar 14, 2026

BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN

Mar 14, 2026

Mar 13, 2026

BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Insider Monkey

Mar 13, 2026

Inflation Data: What is the target price for BioMarin Pharmaceutical Inc stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn

Mar 13, 2026

EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga

Mar 13, 2026

Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka

Mar 13, 2026

BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference - Yahoo Finance

Mar 13, 2026

Mar 12, 2026

BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com South Africa

Mar 12, 2026

BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria

Mar 12, 2026

Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com UK

Mar 12, 2026

Jefferies reiterates Buy on BioMarin stock after DMD trial data By Investing.com - Investing.com Canada

Mar 12, 2026

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire

Mar 12, 2026

First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Mar 11, 2026

BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK

Mar 11, 2026

BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView

Mar 11, 2026

BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView

Mar 11, 2026

Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Mar 11, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat

Mar 11, 2026

Mar 10, 2026

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN) - simplywall.st

Mar 10, 2026

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga

Mar 10, 2026